Since the start of the SARS-CoV-2 pandemic, several treatment options have been proposed (e.g. steroids, heparin, antivirals, and monoclonal antibodies). Remdesivir was the first antiviral approved for the treatment of COVID-19, even though controversial evidence exists concerning the efficacy. Therefore, we aimed to conduct a study to evaluate if the use of remdesivir was associated with lower mortality in patients with COVID-19.
Reduced risk of death in people with SARS-CoV-2 infection treated with remdesivir: a nested case-control study / De Vito, A., Poliseno, M., Colpani, A., Zauli, B., Puci, M.V., Santantonio, T., Meloni, M.C., Fois, M., Fanelli, C., Saderi, L., Fois, A., Fiore, V., Sotgiu, G., Babudieri, S., Lo Caputo, S., Madeddu, G.. - In: CURRENT MEDICAL RESEARCH AND OPINION. - ISSN 0300-7995. - (2022), pp. 1-15. [10.1080/03007995.2022.2129801]
Reduced risk of death in people with SARS-CoV-2 infection treated with remdesivir: a nested case-control study
De Vito, Andrea
;Colpani, Agnese;Zauli, Beatrice;Puci, Mariangela Valentina;Meloni, Maria Chiara;Fois, Marco;Fanelli, Chiara;Saderi, Laura;Fois, Alessandro;Fiore, Vito;Sotgiu, Giovanni;Babudieri, Sergio;Madeddu, Giordano
2022-01-01
Abstract
Since the start of the SARS-CoV-2 pandemic, several treatment options have been proposed (e.g. steroids, heparin, antivirals, and monoclonal antibodies). Remdesivir was the first antiviral approved for the treatment of COVID-19, even though controversial evidence exists concerning the efficacy. Therefore, we aimed to conduct a study to evaluate if the use of remdesivir was associated with lower mortality in patients with COVID-19.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
